Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Erlangen-Nürnberg Medical School
Patients with low-risk prostate cancer will receive HDR-Brachytherapy: 2 x 13,5 Gy.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age \> 18
Histologically confirmed prostate cancer
Gleason Score of index lesion ≤ 6 (3+3)
Tumor stage: cT1-2a cN0 cM0
Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant lesion contralateral. No more than 25% of the punch should be affected. Therefore a 3D-TPM-biopsy is mandatory before treatment.
PSA ≤ 10/ng/ml
Prostate volume \< 60 m\^3
No distant metastasis
Life expectancy \> 10 years
Informed consent
You may not be if
Tumor stage ≥ T2b
Known metastasis: N+ and/or M1
General anesthesia or peridural anesthesia is not possible
Coagulation disorder
Clareo Health | Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
